CZMWF (Carl Zeiss Meditec AG) ROCE %: 0.28% (As of Dec. 2025)


CZMWF Carl Zeiss Meditec AG CZMWF
70 GF Score
Price $31.42
GF Value $85.82
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG ROCE %?

Carl Zeiss Meditec AG CZMWF 70 ROCE % is 0.28% as of Dec. 2025. GuruFocus rates CZMWF with a GF Score™ of 70/100 and a GF Value™ of $85.82 (Significantly Undervalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Carl Zeiss Meditec AG's annualized ROCE % for the quarter that ended in Dec. 2025 was 0.28%.

Carl Zeiss Meditec AG  (OTCPK:CZMWF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Carl Zeiss Meditec AG ROCE % Related Terms

Carl Zeiss Meditec AG ROCE % Historical Data

* Premium members only.

The historical data trend for Carl Zeiss Meditec AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carl Zeiss Meditec AG ROCE % Chart

Carl Zeiss Meditec AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.01 17.97 18.64 10.39 7.97

Carl Zeiss Meditec AG Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.61 10.17 7.15 10.28 0.28
CZMWF
70GF Score
Carl Zeiss Meditec AG CZMWF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carl Zeiss Meditec AG ROCE % Calculation

Carl Zeiss Meditec AG's annualized ROCE % for the fiscal year that ended in Sep. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Sep. 2025 )  (A: Sep. 2024 )(A: Sep. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Sep. 2025 )  (A: Sep. 2024 )(A: Sep. 2025 )
=258.822/( ( (3766.038 - 631.337) + (3994.567 - 638.276) )/ 2 )
=258.822/( (3134.701+3356.291)/ 2 )
=258.822/3245.496
=7.97 %

Carl Zeiss Meditec AG's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=9.368/( ( (3994.567 - 638.276) + (0 - 0) )/ 1 )
=9.368/( ( 3356.291 + 0 )/ 1 )
=9.368/3356.291
=0.28 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.28% mean?
Carl Zeiss Meditec AG (CZMWF) has a ROCE % of 0.28% as of Dec. 2025.
Is Carl Zeiss Meditec AG's ROCE % too high?
Carl Zeiss Meditec AG's current ROCE % is 0.28%. The Medical Devices & Instruments industry median ROCE % is 2.23. Carl Zeiss Meditec AG's value of 0.28% is 87.4% below this industry median. Overall, Carl Zeiss Meditec AG has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's ROCE % compare to ISRG and BDX?
Carl Zeiss Meditec AG's ROCE % of 0.28% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Carl Zeiss Meditec AG's value of 0.28% is 87.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carl Zeiss Meditec AG's current ROCE % of 0.28% is 87.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carl Zeiss Meditec AG's current ROCE % is 0.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG (CZMWF) is currently considered Significantly Undervalued. The stock's GF Value™ is $85.82, compared to a current price of $31.42 — trading 63.4% below its estimated fair value. The current ROCE % is 0.28% and 87.4% below the Medical Devices & Instruments industry median of 2.23. Carl Zeiss Meditec AG's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Carl Zeiss Meditec AG (CZMWF), the current ROCE % is 0.28% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carl Zeiss Meditec AG (CZMWF) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of $31.42 is trading 63.4% below its estimated GF Value™ of $85.82. GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.

Key valuation signals for CZMWF:

  • ROCE %: 0.28%
  • GF Value™: $85.82 vs. price of $31.42 (63.4% below fair value)
  • GF Score™: 70/100 with 4 warning signs
  • Industry Position: 87.4% below the Medical Devices & Instruments median

No single metric tells the full story. See the CZMWF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
70GF Score

Get the complete analysis for CZMWF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.42
Price
$85.82
GF Value